|
🐜
|
Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
14 auth.
N. Galiè,
H. Olschewski,
R. Oudiz,
F. Torres,
A. Frost,
H. Ghofrani,
D. Badesch,
M. McGoon,
V. McLaughlin,
E. Roecker,
...
M. Gerber,
C. Dufton,
B. Wiens,
L. Rubin
|
9 |
2008 |
9
🐜
|
|
🐜
|
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
11 auth.
M. McGoon,
A. Frost,
R. Oudiz,
D. Badesch,
N. Galiè,
H. Olschewski,
...
V. McLaughlin,
M. Gerber,
C. Dufton,
D. Despain,
L. Rubin
|
7 |
2006 |
7
🐜
|
|
🐜
|
Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials
21 auth.
M. Metra,
Eric J. Eichhorn,
W. Abraham,
J. Linseman,
M. Böhm,
R. Corbalán,
D. DeMets,
T. De Marco,
U. Elkayam,
M. Gerber,
...
M. Komajda,
Peter P. Liu,
V. Mareev,
S. Perrone,
P. Poole‐Wilson,
E. Roecker,
J. Stewart,
K. Swedberg,
M. Tendera,
B. Wiens,
M. Bristow
|
6 |
2009 |
6
🐜
|
|
🐢
|
Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Study
12 auth.
H. Black,
G. Bakris,
M. Weber,
Robert G. Weiss,
M. E. Shahawy,
R. Marple,
...
G. Tannoury,
S. Linas,
B. Wiens,
J. Linseman,
R. Roden,
M. Gerber
|
6 |
2007 |
6
🐢
|
|
🐬
|
The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects.
T. Dunn,
M. Gerber,
A. S. Shen,
E. Fernandez,
M. Iseman,
R. Cherniack
|
6 |
1986 |
6
🐬
|
|
🐬
|
Allosteric Modification of Oxygen Delivery by Hemoglobin
J. Wahr,
M. Gerber,
J. Venitz,
N. Baliga
|
5 |
2001 |
5
🐬
|
|
🐜
|
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
21 auth.
A. Feldman,
R. Oren,
W. Abraham,
J. Boehmer,
P. Carson,
Eric J. Eichhorn,
E. Gilbert,
A. Kao,
C. Leier,
B. Lowes,
...
M. Mathier,
F. Mcgrew,
M. Metra,
L. Zisman,
S. Shakar,
S. Krueger,
A. Robertson,
B. G. White,
M. Gerber,
Gwyn E Wold,
M. Bristow
|
4 |
2007 |
4
🐜
|
|
🐜
|
Rationale and design of the enoximone clinical trials program.
17 auth.
B. Lowes,
S. Shakar,
M. Metra,
A. Feldman,
Eric J. Eichhorn,
J. Freytag,
M. Gerber,
J. Liard,
Craig Hartman,
R. Gorczynski,
...
Gwyn Evans,
J. Linseman,
J. Stewart,
A. Robertson,
E. Roecker,
D. DeMets,
M. Bristow
|
4 |
2005 |
4
🐜
|
|
🐬
|
NO CLINICALLY RELEVANT PHARMACOKINETIC INTERACTION BETWEEN AMBRISENTAN AND SILDENAFIL
C. Dufton,
M. Gerber,
O. Yin,
C. Brandquist,
H. Ghofrani
|
4 |
2006 |
4
🐬
|
|
🦁
|
AMBRISENTAN HAS NO CLINICALLY RELEVANT EFFECT ON THE PHARMACOKINETICS OR PHARMACODYNAMICS OF WARFARIN
M. Gerber,
C. Dufton,
H. Pentikis,
L. Zhu,
H. Ghofrani
|
4 |
2006 |
4
🦁
|
